1 / 2

In-Vitro Diagnostics Market To Reach USD 87.11 Billion By 2026; Increasing Prevalence of Cancer Will Enable Growth

In-vitro Diagnostics Market: Launch Of Phadia 200 For Diagnosis Of Allergy & Autoimmune Conditions Will Boost Growth

saurabhrj
Télécharger la présentation

In-Vitro Diagnostics Market To Reach USD 87.11 Billion By 2026; Increasing Prevalence of Cancer Will Enable Growth

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Title : In-Vitro Diagnostics Market To Reach USD 87.11 Billion By 2026; Increasing Prevalence of Cancer Will EnableGrowth In-vitro Diagnostics Market To Exhibit a CAGR of4.5% Description : In-vitro Diagnostics Market: Launch Of Phadia 200 For Diagnosis Of Allergy & Autoimmune Conditions Will BoostGrowth Content: Introduction of new techniques for disease diagnosis is a key factor driving the global in- vitro diagnostics market, states Fortune Business Insights in a report, titled “In-vitro Diagnostics Market Size, Share & Industry Analysis, By Product Type (Instruments, Reagents & Consumables), By Technique (Immunodiagnostics, Clinical Chemistry, Molecular Diagnostics, Point of Care, Hematology and Others), By Application (Infectious Diseases, Cardiology, Oncology, Gastroenterology, Others), By End User (Clinical Laboratories, Hospitals, Physicians Offices, Others) and Regional Forecast, 2019-2026.” According to the report, the global in-vitro diagnostics market was valued at USD 61.22 Billion in 2018 is predicted to reach USD 87.11 Billion by 2026, exhibiting a CAGR of 4.5% during the forecastperiod. An Overview of the Impact of COVID-19 on thisMarket: The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses acrossindustries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic. We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of corona virus outbreak across industries to help you prepare for thefuture. Click here to get the short-term and long-term impact of COVID-19 on this[Market]. For More Information : https://www.fortunebusinessinsights.com/industry- reports/biochips-based-in-vitro-diagnostics-market-100177 Increasing Prevalence of Chronic and Infectious Disease Will EnableGrowth The launch of diagnostic and rapid testing tools by leading market players will propel growth of the global in-vitro diagnostics market. For instance, Thermo Fisher Scientific launched Phadia 200 for diagnosis of allergy & autoimmune conditions. The launch of Phadia 200 is anticipated to increase the revenue of the company. According to the report, the reagents and consumables segment will account for a major portion in the global in-vitro diagnostics market during the forecast period owing to the adoption of self- test andpoint-of-care

  2. devices. Furthermore, the instrument segment is likely to grow at a moderately slower pace during the forecast period. Rising technological advancement is predicted to aid growth of the segment. Moreover, the increasing cases of cancer and infectious disease around the world will further accelerate global in-vitro diagnostics marketgrowth. Launch of Altostar Molecular Diagnostics Workflow Will BoostGrowth Altona Diagnostics GmbH, molecular diagnostic testing solutions company launched a CE- IVD marked AltoStar Molecular Diagnostics Workflow. AltoStar Molecular Diagnostics a flexible and efficient automatic system that automates the entire workflow from sample preparation upto analysis. Fortune Business Insights states the launch of CE-IVD marked AltoStar Molecular Diagnostics Workflow is expected to boost the in-vitro diagnostics market revenue. Furthermore, the oncology segment is likely to grow at a considerable rate during the forecast period. Rising adoption and availability of advanced home care kits such as fecal occult blood test (FOBT) for diagnosis of colon cancer in homecare settings is one of the major factor likely to fuel demand for the oncology segment, which, will, in turn, uplift the global in-vitro diagnostics marketshares. More Trending Topics From Fortune BusinessInsights@ Examination Lights Market, Share, Growth, Sales and Drivers Analysis Research Report 2026 Examination Lights Market to Reach $259.6 Million by 2026; Rising Preference for LEDLights over Filament Bulbs to Pave Way for New Opportunities: Fortune BusinessInsights™

More Related